Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label，Randomized, Controlled, Multicenter Study of Adalimumab and Tofacitinib in the Treatment of Active Takayasu Arteritis

NCT05151848 is registered in ClinicalTrials.gov with Chinese SLE Treatment And Research Group as lead sponsor.

NCT NCT05151848
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05151848 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label，Randomized, Controlled, Multicenter Study of Adalimumab and Tofacitinib in the Treatment of Active Takayasu Arteritis
Lead sponsor
Chinese SLE Treatment And Research Group
Phase
Phase 4
Overall status
Unknown status
Start date
January 5, 2022
Completion date
January 15, 2026
Enrollment
100 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

takayasu arteritis